WallStreetZenWallStreetZen

NASDAQ: NMRD
Nemaura Medical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for NMRD

Based on 2 analysts offering 12 month price targets for Nemaura Medical Inc.
Min Forecast
$6.00+1,032.08%
Avg Forecast
$6.50+1,126.42%
Max Forecast
$7.00+1,220.75%

Should I buy or sell NMRD stock?

Based on 2 analysts offering ratings for Nemaura Medical Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NMRD stock forecasts and price targets.

NMRD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
EF Hutton
Bottom 4%
4
Strong BuyReiterates$6.00+1,032.08%2023-03-30
HC Wainwright & Co.
Bottom 14%
14
BuyMaintains$7.00+1,220.75%2023-02-27

1 of 1

Forecast return on equity

Is NMRD forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is NMRD forecast to generate an efficient return on assets?
Company
-95.87%
Industry
10.11%
NMRD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NMRD revenue growth forecast

How is NMRD forecast to perform vs Medical Devices companies and vs the US market?
Company
1,384.94%
Industry
5.6%
Market
16.94%
NMRD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NMRD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NMRD vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
NMRD$0.53$6.50+1,126.42%Strong Buy
NSPR$1.85$4.75+156.76%Strong Buy
IINN$1.40$13.00+828.57%Strong Buy
STRR$1.05N/AN/A
TNON$1.10$6.00+445.45%Strong Buy
View Top Medical Device Stocks

Nemaura Medical Stock Forecast FAQ

Is Nemaura Medical Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: NMRD) stock is to Strong Buy NMRD stock.

Out of 2 analysts, 1 (50%) are recommending NMRD as a Strong Buy, 1 (50%) are recommending NMRD as a Buy, 0 (0%) are recommending NMRD as a Hold, 0 (0%) are recommending NMRD as a Sell, and 0 (0%) are recommending NMRD as a Strong Sell.

If you're new to stock investing, here's how to buy Nemaura Medical stock.

What is NMRD's forecast return on equity (ROE) for 2024-2024?

(NASDAQ: NMRD) forecast ROE is N/A, which is considered weak.

What is NMRD's Price Target?

According to 2 Wall Street analysts that have issued a 1 year NMRD price target, the average NMRD price target is $6.50, with the highest NMRD stock price forecast at $7.00 and the lowest NMRD stock price forecast at $6.00.

On average, Wall Street analysts predict that Nemaura Medical's share price could reach $6.50 by Mar 30, 2024. The average Nemaura Medical stock price prediction forecasts a potential upside of 1,126.42% from the current NMRD share price of $0.53.

What is NMRD's forecast return on assets (ROA) for 2024-2024?

(NASDAQ: NMRD) forecast ROA is -95.87%, which is lower than the forecast US Medical Devices industry average of 10.11%.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.